Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clear as a bell!

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Oct 04, 2024 2:39pm

167 Views

Post# 36253686

RE:RE:RE:RE:Clear as a bell!

Quentin, all your comments are valid. The market, so far, the market is reacting positively. So far, anyway, ONC has not raised any funds, unless they have been using the ATM. In 25 years I have been involved with this company I can't recall them ever allowing the cash needs to drop below 12 months. My conclusion is they are working towards a partner or buyout. They need to accomplish this becasue they are 2 years away from any conclusion. Lets hope. a buyout is imminent.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project